Effect of TT30 on hemolysis of PNH RBCs from untreated and eculizumab-treated PNH patients in the EASA. (A) PNH patients not on eculizumab. Absolute percentage lysis of PNH RBCs in aNHS with and without TT30. Lines represent the mean values of 26 experiments (10 in duplicate, 1 in triplicate, and 3 in quadruplicate) on RBCs obtained from 14 untreated PNH patients (2 patients were drawn 4 times, 3 patients drawn 3 times, and the remaining 9 just once); error bars represent SEM. The continuous thin black line indicates aNHS; dashed thin black line, TT30 0.3μM; dashed bold black line, TT30 1μM; and continuous bold black lines, TT30 3μM. (B) PNH patients on eculizumab. Absolute percentage lysis of PNH RBCs in aNHS with and without TT30. Lines represent the mean values of 26 experiments (12 in duplicate, 1 in triplicate, and 3 in quadruplicate) on RBCs obtained from 6 PNH patients on eculizumab treatment (1 patient was drawn 14 times, 1 patient drawn 9 times, and the remaining 3 just once); error bars represent SEM. The continuous thin black line indicates aNHS; dashed thin black line, TT30 0.3μM; dashed bold black line, TT30 1μM; and continuous bold black lines, TT30 3μM.